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ABSTRACT
The rewarding properties of some abused drugs are thought to reside in their ability to increase striatal dopamine
levels. Similar increases have been shown in response to expectation of a positive drug effect. The actions of opioid
drugs on striatal dopamine release are less well characterized. We examined whether heroin and the expectation of
heroin reward increases striatal dopamine levels in human opioid addiction. Ten opioid-dependent participants main-
tained on either methadone or buprenorphine underwent [11C]raclopride positron emission tomography imaging.
Opioid-dependent participants were scanned three times, receiving reward from 50-mg intravenous heroin
(diamorphine; pharmaceutical heroin) during the first scan to generate expectation of the same reward at the second
scan, duringwhich they only received 0.1-mg intravenous heroin. There was no heroin injection during the third scan.
Intravenous 50-mg heroin during the first scan induced pronounced effects leading to high levels of expectation at the
second scan. There was no detectable increase in striatal dopamine levels to either heroin reward or expectation of
reward. We believe this is the first human study to examine whether expectation of heroin reward increases striatal
dopamine levels in opioid addiction. The absence of detectable increased dopamine levels to both the expectation and
delivery of a heroin-related rewardmay have been due to the impact of substitute medication. It does however contrast
with the changes seen in abstinent stimulant users, suggesting that striatal dopamine release alone may not play such
a pivotal role in opioid-maintained individuals.
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INTRODUCTION
The euphoric effect of stimulants has been shown to cor-
relate with striatal dopamine release, and increases in
dopamine have also been reported with alcohol, nicotine
and cannabis (Volkow et al. 2011), but not consistently
nor always associated with a subjective ‘high’ (Boileau
et al. 2003; Montgomery et al. 2007; Stokes et al. 2009).
In contrast, we previously found that 50-mg intravenous
heroin, despite producing a very profound ‘high’, did not
increase dopamine levels in methadone-maintained
opioid-dependent individuals (Daglish et al. 2008).
However, there is evidence in primates that dopamine cell
firing appears to be associated with the expectation,
rather than the receipt of reward (see Schultz 2010).
Consistent with this in humans, expectation of methyl-
phenidate has been shown to result in larger increases in
brain metabolism in cocaine-dependent individuals, than
when it is unexpected (Volkow et al. 2003). Also dopa-
mine release in response to cocaine cues has been dem-
onstrated in the dorsal striatum of individuals abusing
cocaine (Volkow et al. 2006; Wong et al. 2006).
Increased dopamine levels in the right putamen have also
been reported to heroin-related cues in abstinent opioid-
dependent individuals (Zijlstra et al. 2008). Such
increases in the dorsal striatum are consistent with its
role in habit learning and compulsive drug use (Everitt
& Robbins 2005). These increases in cue-induced
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dopamine levels occur despite chronic drug abuse being
associated with a hypodopaminergic state (Volkow et al.
2010).
It is important to characterize the role of dopamine
in the various drugs of abuse, because it has been
argued that opioid and psychostimulant addiction are
neurobiologically distinct with important implications
for theories of addiction and its treatment (Badiani et al.
2011). We therefore developed our previous protocol
using [11C]raclopride positron emission tomography
(PET) imaging (Daglish et al. 2008), to further test two
hypotheses in opioid-dependent participants: (1) striatal
dopamine levels would increase with expectation of
heroin reward and (2) striatal dopamine levels would
increase after intravenous heroin.
MATERIALS AND METHODS
The study received approval from the Bath National
Health Service Research Ethics Committee and the
Administration of Radioactive Substances Advisory
Committee, UK. All participants gave written informed
consent prior to study procedures. Male participants aged
over 18 years old, who met the Fourth Edition of the
Diagnostic and Statistical Manual (American Psychiatric
Association 1994) criteria for opioid dependence, cur-
rently maintained on methadone (≥30 mg/day) or
buprenorphine (<8 mg/day), were recruited from outpa-
tient addiction services. Participants were not dependent
on or misusing any other substance other than nicotine,
or had a history of clinically significant psychiatric or
medical illness, or were taking other psychotropic medi-
cation. All participants provided a negative urinalysis for
illicit substances of abuse before each scan.
PET data acquisition
Each participant underwent three [11C]raclopride PET
scans, separated by at least 1week determined by scanner
availability [mean ± standard deviation (SD) interval
between first and second PET scans 14.0 ± 7.6 days;
mean ± SD interval between second and third PET scans
12.5 ± 7.4 days]. Each PET scan occurred at a similar
time of day and participants were over 24 hours after
their last dose of methadone or buprenorphine, which
they deferred taking until after the scan. At the
first (‘reward’) PET scan, participants were told they
would receive an injection of pharmaceutical heroin
(diamorphine; subsequently referred to as heroin),
although the dose was undisclosed as in our previous
study (Daglish et al. 2008). Fifty milligrams of heroin in
5 ml of water was given intravenously, 55 minutes into
the 100-minute scan. At their second (‘expectation’) PET
scan, participants were also told that theywould receive a
heroin injection during the scan and again the dose was
undisclosed. On this occasion, however, participants were
given a low and undetectable dose of 0.1-mg heroin in
5 ml of water intravenously, 55 minutes into the 100-
minute scan. In the reward and expectation scans we
heightened their expectation of heroin reward by giving
time checks every 10 minutes and counted down the last
30 seconds, and using awebcam so participants could see
the injection, including the salient blood flashback. At
their third (‘no-drug’) PET scan participants were told
they would not receive an injection of heroin. This scan
was used to measure [11C]raclopride binding, free from
any expectation or rewarding effects. All participants
underwent T1-weighted magnetic resonance imaging
(MRI) on a separate day, with a Philips 1.5T Gyroscan
Intera scanner (Philips, Best, The Netherlands) to
produce structural images for reference.
All PET scans were conducted using an ECAT HR+
962 scanner (CTI/Siemens, Knoxville, TN, USA), with
an axial field of view of 15.5 cm. A 10-minute trans-
mission scan was acquired prior to each emission scan
to correct for tissue attenuation. Dynamic emission
scans were acquired in three-dimensional mode using
a standard acquisition protocol (38 frames over 100
minutes; Stokes et al. 2010). Each participant received
240 MBq of [11C]raclopride administered as an initial
intravenous bolus (922 ml/hour for 60 seconds) fol-
lowed by a constant infusion (8.8 ml/hour) for the
remainder of the scan (Watabe et al. 2000). We used a
bolus infusion of [11C]raclopride to deal with potential
limitations of our previous bolus protocol such as
timing of heroin and [11C]raclopride injection and mini-
mize confounds such as drug-related blood flow effects
by establishing a state of constant equilibrium (Carson
et al. 1997).
Subjective and physiological measures
Before each [11C]raclopride PET scan, participants com-
pleted Beck’s Depressive Inventory (BDI; Beck et al. 1961)
and Spielberger State-Trait Anxiety Inventory (SSAI,
STAI; Spielberger et al. 1983). Visual analogue scales
(VAS; 100 points) were used to rate ‘high’, ‘rush’,
‘gouched’ (local slang for opioid intoxication), ‘urge and
craving’ (to use heroin) and ‘withdrawal’ during their
[11C]raclopride PET scans. Ratings were collected at base-
line, 6 minutes prior to the start of the scan, and at 6, 16,
28, 38, 48, 63, 73, 83, 93 and 5 minutes post-scan.
Opioidwithdrawalwas also assessed before and after each
scan using a Modified Himmelsbach Opiate Withdrawal
Scale (Law et al. 1997). Levels of expectation were meas-
ured using VAS, asking participants how good they
expected the scan and heroin injection to be immediately
before the scan and how good it had been immediately
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after the scan. They were also asked what equivalent
value of street heroin they had been given after reward
and expectation scans.
To objectively assess the effects of heroin on the brain
we used our standard protocol measuring saccadic eye
movements immediately before each VAS data collection
point (Wilson et al. 1993). The impact of heroin on res-
piratory depression was monitored with pulse oximetry.
Blood for methadone plasma concentrations was taken
immediately before each scan and quantified using
a modified liquid–liquid extraction followed by gas
chromatography–mass spectrometry (Paterson, Cordero
& Burlinson 2004).
PET data analysis
All dynamic scans were motion corrected using frame-
by-frame realignment in Piwave 7.0 (in-house software;
Imperial College London, London, UK) running in
Matlab® (The MathWorks Inc., Natick, MA, USA;
Montgomery et al. 2006). The resultant dynamic frames
were processed with receptor parametric mapping (RPM)
to generate an add-image (Gunn et al. 1997), which was
a weighted sum of all 38 frames. MRIs were co-registered
to the individual add-images using Statistical Parametric
Mapping 5 (SPM5; Functional Imaging Laboratory, Uni-
versity College London, UK) and then normalized into
Montreal Neurological Institute (MNI) space (Interna-
tional Consortium for Brain Mapping) using bias-
corrected segmentation in SPM5.
For the region of interest (ROI) analysis, the inverse
deformation parameters obtained from the segmentation
process were applied to a functional striatal atlas
(Martinez et al. 2003). Striatal and cerebellar ROIs were
defined using an atlas composed of the three functional
subdivisions of the striatum: limbic (ventral), associative
(pre-commissural dorsal putamen, pre-commissural
dorsal caudate and post-commissural dorsal caudate)
and sensorimotor striatum (post-commissural putamen)
and cerebellum. The individual deformed atlases were
used to sample the add-images described earlier using
Analyze software (http://www.analyzedirect.com;).
Accounting for radioactive decay, we previously reported
[11C]raclopride equilibrium stability of 0.06% per minute
over the equilibrium period using this bolus infusion
protocol (Stokes et al. 2009).
Binding potential (BPND) values for [11C]raclopride in
each striatal regionwere calculated as the ratio of striatal
counts to cerebellar counts, minus 1, over the steady-
state time periods (Lammertsma & Hume 1996). Frames
19–22 (35.5–55.5 minutes) corresponded to the pre-
heroin injection equilibrium period and were used to
generate ‘early’ steady-state phase add-images. Frames
25–38 (57.5–100.5 minutes) corresponded to the post-
heroin injection equilibrium period andwere used to gen-
erate ‘late’ steady-state phase add-images (Egerton et al.
2009). The study was designed so that any difference in
[11C]raclopride binding between reward and expectation
scans would be due to the effect of heroin, while differ-
ences in [11C]raclopride binding between expectation and
no-drug scans would be due to the effect of expectation
(see Fig. 1).
Exploratory voxelwise analysis was also undertaken
using image algebra within SPM5 running in Matlab®
(The MathWorks Inc.) to create parametric BPND maps.
The steady-state add-image voxels were divided by the
cerebellar counts minus 1. Percentage increase images
between the early and late phase BPND maps were calcu-
lated for reward, expectation and no-drug scans using the
equation
i i
i
1 2
1
100
−⎛⎝⎜ ⎞⎠⎟ × , where i1 is the early phase para-
metric image and i2 is the late phase parametric image.
The resulting imageswere normalized to a [11C]raclopride
template image in MNI space and smoothed using a
6 mm3 full width at half-maximum Gaussian kernel.
Statistical analysis
All statistical comparisons, apart from voxelwise analy-
ses, were performed using SPSS 18.0 (SPSS, Chicago, IL,
USA). All t-tests were two-tailed. Paired samples t-tests
were used to compare subjective measures. Correlations
between parametric data were assessed using Pearson’s
product–moment correlation coefficient. Differences in
early and late steady-state phases within and between
different scanswere investigated using repeatedmeasures
analysis of variance (ANOVA), with striatal region as a
within-subject factor. Heterogeneity of covariance was
tested with the Mauchly sphericity test and degrees of
freedom modified using the Greenhouse–Geisser adjust-
ment, where appropriate.
Heroin effect Expectation effect
‘Reward’ scan ‘Expectation’ scan ‘No-drug’ scan
Heroin reward No heroin reward No heroin reward
Expectation Expectation No expectation
Figure 1 Drug and expectation factors
present in each participants’ scan
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Voxelwise analyses were performed within SPM5
using an explicit striatal mask. Differences in early and
late steady-state phases within and between different
scans were compared using a paired t-test. A height
threshold of P < 0.001 and volume-corrected cluster
threshold of P < 0.05 were used for statistical signifi-
cance (Stokes et al. 2009).
RESULTS
Eleven opioid-dependent individuals started the three-
scan protocol; however, one withdrew after the first scan
due to subsequent failure of [11C]raclopride synthesis,
leaving 10 who completed all three [11C]raclopride PET
scans. The mean ± SD participant age was 37.8 ± 9.0
years. Nine participants were receivingmethadonemain-
tenance (mean ± SD daily dose 50.5 ± 25.2 mg) and one
buprenorphinemaintenance (5 mg/day).Themean ± SD
length of prior opioid use was 13.9 ± 6.3 years. All par-
ticipants were tobacco smokers and had last smoked
cannabis more than 2 months prior to imaging. Six
participants had no recent alcohol consumption, with
the remaining participants consuming 8–18 units (64–
144 g) of alcohol per week. Occasional stimulant use was
reported by all participants, with last use over 2 years
previously for all but two (2 months, 6 months).
Mean ± SDBDI and SSAI scores did not differ significantly
between scans and were as follows: reward scan (BDI
12.9 ± 9.5; SSAI 39.1 ± 12.8), expectation scan (BDI
12.6 ± 10.1; SSAI 34.5 ± 8.8) and no-drug scan
(BDI 12.9 ± 10.9; SSAI 33.3 ± 9.7). Themean ± SD STAI
score was 43.7 ± 11.3. These scores reflect only mild
symptoms of anxiety and depression.
Subjective and physiological measures
The key experimental objective of inducing expectation
for heroin reward in both reward and expectation scans
was achieved (Fig. 2). Expectation levels as measured by
mean pre-scan ‘good’ VAS scores were higher for the
expectation scan than the reward scan (t9 = −2.18,
P = 0.057). A significant difference was seen between
mean pre-scan ‘good’ VAS scores of reward and no-drug
scans (t9 = 3.11, P = 0.013), and of expectation and
no-drug scans (t9 = 5.61, P < 0.001). All participants in
the reward scan and 7 of 10 participants in the expecta-
tion scan believed they had experienced effects of heroin
after the injection. The mean ± SD estimated equivalent
value of street heroin receivedwas £18.00 ± 13.20 in the
reward scan and £5.50 ± 4.40 in the expectation scan
(£10 buys approximately 0.2-g heroin).
In the reward scan following heroin injection, there
were pronounced and significant increases in VAS scores
for the positive effects of heroin (Fig. 3) such as high
(mean ± SD change 51.8 ± 30.6, t9 = 5.36, P < 0.001),
rush (47.8 ± 37.7, t9 = 4.01, P = 0.003) and gouched
(29.0 ± 31.8, t9 = 2.89, P = 0.018). There were smaller
and non-significant increases seen in these VAS scores in
the expectation scan and in the no-drug scan, all partici-
pants scored zero throughout. During all scans ratings
of withdrawal and urge and craving to use heroin were
low and did not change significantly as a result of any
interventions.
The predicted slowing and impairment of saccadic eye
movements was observed in the reward scan, but not in
the expectation scan consistent with our previous study
(Daglish et al. 2008). Oxygen saturation levels remained
stable and within normal limits in all participants
throughout the expectation and no-drug scans, but fell in
the reward scan to a mean ± SD minimum level of
83.3% ± 10.3.There was no significant difference seen in
pre-scan methadone plasma levels between the three
scans (mean ± SD reward scan 255.6 ± 201.4 ng/ml;
expectation scan 228.9 ± 229.4 ng/ml; no-drug scan
210.0 ± 160.4 ng/ml; ANOVA, F2,14 = 0.37, P = 0.70).
[11C]raclopride PET
No significant effect of expectation on [11C]raclopride
BPND in any striatal ROI was found in two comparisons:
[11C]raclopride BPND in early and late steady-state
phases within the expectation scan (ANOVA F1,9 = 0.08,
P = 0.78), and between early and late steady-state
phases in the expectation and no-drug scans (ANOVA
F1,9 = 0.32, P = 0.59). We also found no significant effect
from 50 mg of heroin on [11C]raclopride BPND values in
any striatal ROI. Two comparisons were undertaken:
[11C]raclopride BPND in early and late steady-state phases
within the reward scan (ANOVA F1,9 = 0.06, P = 0.82),
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Figure 2 Mean ‘good’ visual analogue scale (VAS) scores, pre and
post each scan. Standard error bars shown
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and between early and late steady-state phases in the
reward and expectation scans (ANOVA F1,9 = 0.11,
P = 0.75). In addition there were no significant correla-
tions between VAS high scores and [11C]raclopride BPND
values in any striatal region. Table 1 shows mean BPND
values in each of the scans.
Our exploratory voxelwise analysis generally con-
firmed the ROI analysis with no significant differences
found in early and late steady-state phases between
reward and expectation scans or between expectation
and no-drug scans. There were small clusters in the
reward and expectation scans in which BPND increased
significantly from early to late steady-state phases
(Table 2); no significant decreases were seen. There were
no significant increases or decreases in BPND within the
no-drug scan.
DISCUSSION
This is the first study to our knowledge to examine
whether the expectation of heroin reward increases
striatal dopamine levels in human opioid addiction.
Despite our experimental paradigm producing marked
expectation, no increase in dopamine levels in any striatal
region was detected. In addition there was no increase in
regional striatal dopamine levels following a rewarding
dose (50 mg) of intravenous heroin.
Salient drug cues and giving heroin in their first
[11C]raclopride PET scan resulted in increased levels of
expectation at the second scan in all participants. We
enhanced the cues for the opioid-dependent participants
compared with our previous study (Daglish et al. 2008).
Because passive administration of drugs has been shown
to result in smaller increases in dopamine compared with
a self-administration (Leyton 2007), a webcam was used
so the participants could see the highly salient ‘flashback’
and injection of heroin. Leyton emphasizes the impor-
tance of cues in his ‘two-factor dopamine model’ based
on evidence from studies with psychostimulants (Leyton
2007). However, his model posits that low dopamine
responsivity would be associatedwith the absence of cues
rather than the salient cues in our study. Despite our
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Figure 3 Mean ‘high’ visual analogue scale
(VAS) scores, plotted against time for each
scan
Table 1 Mean ± standard deviation [11C]raclopride binding potential in each scan.
Striatal region
Reward scan Expectation scan No-drug scan
Early Late Early Late Early Late
Sensorimotor
Left 2.44 ± 0.33 2.45 ± 0.28 2.47 ± 0.26 2.48 ± 0.27 2.57 ± 0.31 2.54 ± 0.36
Right 2.32 ± 0.38 2.34 ± 0.33 2.44 ± 0.30 2.44 ± 0.30 2.58 ± 0.36 2.56 ± 0.39
Associative
Left 1.97 ± 0.33 1.96 ± 0.29 2.02 ± 0.30 1.99 ± 0.27 2.19 ± 0.32 2.11 ± 0.33
Right 2.19 ± 0.31 2.21 ± 0.29 2.25 ± 0.29 2.22 ± 0.28 2.37 ± 0.33 2.31 ± 0.35
Limbic
Left 1.95 ± 0.31 1.96 ± 0.26 2.10 ± 0.20 2.11 ± 0.20 2.26 ± 0.37 2.18 ± 0.36
Right 1.91 ± 0.29 1.90 ± 0.22 1.90 ± 0.26 1.90 ± 0.28 1.99 ± 0.32 2.01 ± 0.25
Early = early steady-state phase; Late = late steady-state phase.
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highly salient injection procedure, we were still not able
to show any changes in striatal dopamine levels in
substitute-maintained opioid-dependent participants.
Previous neuroimaging studies in drug addiction have
reported increased dopamine levels in abstinent individu-
als associated with salient videos, but have measured
‘craving or urge’, ‘intentions to use’, ‘desire’ or ‘need or
want’ rather than ‘expectation’ (Volkow et al. 2006,
2010;Wong et al. 2006; Zijlstra et al. 2008). While there
are similarities between expectation and craving, expec-
tation generally implies looking forward to something
positive or good, whereas craving has a sense of need and
urgency that may be more present in abstinence. In con-
trast to expectation, craving to use did not vary during
the scans, probably because participants knew they were
going to receive heroin and/or their substitute medica-
tion. It is therefore possible that increased striatal dopa-
mine levels are associated with craving rather than
expectation.
Expectation of therapeutic benefit from a dopami-
nergic agonist in patients with Parkinson’s disease has
been shown to increase dopamine levels in the ventral
striatum and perception of clinical benefit to increases in
the dorsal striatum (de la Fuente-Fernández et al. 2002).
Similarly expectation of analgesia has been shown to be
associatedwith increased dopamine levels in the striatum
(Scott et al. 2007).The anticipation of therapeutic benefit
in patients with Parkinson’s disease has been likened to
the expectation of reward. However, patients expect to
gain relief from their physical disorder, which is akin
to negative rather than positive reinforcement. Conse-
quently increased dopaminemay be associated with relief
from a negative state (cf. bupropion in smoking cessa-
tion), whereas in our study, the opioid-dependent partici-
pants were not in withdrawal and instead experienced a
‘high’ from their substance of abuse. Another factor may
be that there was 100% certainty they would receive
heroin because a study with Parkinson’s patients
reported that striatal dopamine levels increased maxi-
mally with 75% certainty and not at all with 100% cer-
tainty (Lidstone et al. 2010). Our results are however
consistent with other studies where expectation of caf-
feine in habitual coffee drinkers or of intravenous glucose
in healthy volunteers was not associated with increased
striatal dopamine levels (Kaasinen et al. 2004; Haltia
et al. 2008).
Our findings also speak to Schultz’s work in primates
implicating dopamine neuronal firing in learning and
expectation of reward, on which we based our hypothesis
(Schultz 2010). Schultz, Dayan & Montague (1997)
showed that after repeated pairings of cues followed by
reward, the timing of dopamine neuron activation
changed from just after reward delivery to the time of cue
onset, with a loss of dopaminergic response to the pre-
dicted reward itself. Because reward was defined as
involving a variety of processes including hedonic feel-
ings and generating approach behaviour, it may be that
dopamine is more associated with the latter, which did
not occur in our study because they were given the drug.
However, Schultz also showed that if the conditioned cue
was presented and no subsequent reward delivered, a
reduction in dopamine neuron activity was seen. Consist-
ent with this, our voxelwise analysis of the expectation
scan showed small clusters of reduced dopamine levels
after the non-rewarding dose (0.1 mg) of heroin. While
we report this finding cautiously because it was found on
exploratory analysis, it is to our knowledge the first evi-
dence in humans of dopamine’s involvement in reward
prediction error.
We again found that a rewarding dose (50 mg) of
heroin did not result in significant increases in striatal
dopamine in opioid-maintained individuals (see also
Daglish et al. 2008). Our exploratory voxelwise analysis
revealed small clusters of reduced dopamine levels that
are consistent with a study of another opioid agonist,
alfentanil, in healthy volunteers (Hagelberg et al. 2002).
In contrast a remifentanil infusion has been reported
to increase striatal dopamine levels measured with
Table 2 Areas of significant increase in [11C]raclopride binding potential from early to late steady-state phases within reward and
expectation scans, identified in the exploratory voxelwise analysis.
Striatal region Cluster sizea (voxels) Coordinatesc (x, y, z) t value Correctedb P value
Reward scan
L associative/limbic 43 −12, 22, −6 9.42 < 0.001
L limbic 15 −24, 8, −12 6.89 0.008
Expectation scan
R sensorimotor 38 28, −4, −8 12.02 < 0.001
L limbic 35 −24, 2, −12 7.3 < 0.001
L limbic 26 −18, 20, −8 8.25 0.001
R associative 13 18, 20, 8 7.51 0.021
aCluster sizes correspond to number of voxels of dimension 2 mm3. bP values were after correction for striatal volume. cThe Montreal Neurological
Institute coordinates, corrected P and t values are for the voxel in each cluster containing the peak effect size. L = left; R = right.
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[18F]fallypride PET in healthy volunteers and abstinent
alcohol-dependent individuals, but there was no relation-
ship to craving (Spreckelmeyer et al. 2011).
Our finding that striatal dopamine levels were not
increased by a rewarding dose of heroin is consistent
with studies in cocaine or alcohol addiction, showing
blunted methylphenidate-induced or amphetamine-
induced dopamine release (Volkow et al. 1997; Martinez
et al. 2005, 2007). Methylphenidate-stimulated dopa-
mine release has also been shown to be blunted in
abstinent opioid-dependent individuals although no
subjective effects were reported (Martinez et al. 2012).
However, importantly, neither amphetamine nor methyl-
phenidate are the participants’ ‘drug of choice’ given by
the usual route, as was the case in our study. It appears
therefore that changes in dopamine can occur in the
absence of pronounced subjective effects, and that the
rewarding effects of opioids can occur in the absence of
detectable dopamine levels.
While the impact of drug-taking status and opioid
maintenance medications on the dopaminergic system
remains to be fully characterized, it may have been an
important factor in our experiments. Cue-induced
increases in dopamine have been reported in abstinent
cocaine-dependent or opioid-dependent individuals
(Volkow et al. 2006; Wong et al. 2006; Zijlstra et al.
2008), whereas the opioid-dependent participants in
both of our studies were maintained on methadone
(except one participant on buprenorphine) and injecting
heroin intermittently (note it would be unethical and
dangerous to administer heroin to non-maintained indi-
viduals). Pre-clinical evidence suggests that acute admin-
istration of methadone blocks dopamine receptors and
increases dopaminergic turnover, whereas in methadone
addicts lower levels of cerebrospinal fluid homovanillic
acid suggest reduced dopamine turnover (Tamarkin,
Goodwin &Axelrod 1970; Sasame et al. 1972; Clemens &
Sawyer 1974). Therefore a reduction in dopamine turno-
ver could result in difficulty in detecting any dopamine
increase with ‘expectation’ or ‘high’, which may have
been the case in the present study. It may also be that part
of methadone’s efficacy as a maintenance treatment is
due to its ability to blunt dopaminergic responses, thereby
reducing craving and cue reactivity to heroin.
Both our studies, showing no changes in striatal dopa-
mine in opioid-maintained individuals, are however con-
sistent with evidence from animal models. Unlike for
cocaine, studies have shown that opioid reinforcement
is not critically dependent on an intact mesolimbic
dopaminergic system (Pettit et al. 1984; Van Ree &
Ramsey 1987; Gerrits & Van Ree 1996). High impulsivity
in rats is associated with low D2/3 receptor levels in the
ventral striatum, and increased vulnerability to lose
control over cocaine intake and relapse to cocaine
seeking after abstinence but not to heroin use (Dalley
et al. 2007; McNamara et al. 2010). Martinez
et al. (2012) also reported that unlike their studies
with cocaine-dependent individuals, methylphenidate-
stimulated dopamine release did not correlate with
heroin self-administration. A recent comparison also
strongly argued for important distinctions between
psychostimulant and opioid addiction, including in the
dopamine system (Badiani et al. 2011). We therefore
suggest that there is good evidence for dopamine playing
a different role depending on the substance of abuse.
While PET has been a highly useful tool for studying
neurotransmitter systems in man, its sensitivity is
limited. It is therefore possible that any dopamine release
induced either by the expectation of heroin or heroin
itself is too small or localized to be detected by current
[11C]raclopride PET scan and analysis techniques. It is
also possible that the sample size of 10 participants was
too small to detect any dopamine release. The study was
adequately powered (0.8) to detect a 3.6% change in
overall [11C]raclopride binding consistent with other
studies that reported significant changes of 4–5% in
[11C]raclopride binding with cue exposure (Volkow et al.
2006; Wong et al. 2006). The power calculation used
a within-volunteer SD of 3.6% for overall striatal
[11C]raclopride binding, calculated from our previously
reported test–retest study (Stokes et al. 2010). Significant
increases in dopamine to treatment expectation (22%; de
la Fuente-Fernández et al. 2002), stimulant administra-
tion (16%; Volkow et al. 2002) and alcohol administra-
tion (15%; Boileau et al. 2003) have also been reported
with similar or lower participant numbers. In addition,
we saw both increased and decreased BPND values in all
striatal areas without a consistent trend. Using the
observed differences between ‘early versus late’ phases
and between scans, over a hundred participants would
have had to be scanned to generate a significant finding
that is clearly impracticable and unethical. The study had
to overcome two major challenges: firstly that partici-
pants were required to attend for four scans (three PET
and one MRI), and secondly the recruitment of opioid-
dependent individuals without co-morbid stimulant or
benzodiazepine abuse. Consequently, to ensure a suffi-
cient number of such participants were recruited to
robustly test our hypotheses, the study took 5 years to
complete. A further limitation of all [11C]raclopride PET
studies is the uncertainty about what any differences in
BPND represent. While changes are measurable following
both pharmacological and psychological interventions,
these may reflect either changes in synaptic dopamine
concentration or in dopamine D2/3 receptor availability
(Laruelle 2000; Egerton et al. 2009).
In conclusion, we have demonstrated that striatal
dopamine release does not appear to play a key role in
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mediating either the expectation or ‘high’ associatedwith
heroin use in opioid-dependent individuals maintained
on substitute medication. Given how many opioid-
dependent individuals are in maintenance programmes,
it is vital that we understand the impact of substitute
medications on the dopaminergic system. In addition,
there is growing evidence that dopamine is likely to play
differing roles in opioid addiction compared with alcohol
and cocaine addiction (Badiani et al. 2011). Our results
provide further evidence for the debate about the role of
dopamine in opioid addiction because studies in absti-
nence and those on substitute medication suggest its role
may differ, and the impact on clinical outcomes deserves
further investigation.
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